(Q38108391)

29 August 2017

title

Perspectives in the treatment of multiple myeloma (English)

1 reference

29 August 2017

2

1 reference

29 August 2017

Massimo Gentile

1

1 reference

29 August 2017

Carla Mazzone

3

1 reference

29 August 2017

Eugenio Lucia

4

1 reference

29 August 2017

Ernesto Vigna

5

1 reference

29 August 2017

Fortunato Morabito

6

1 reference

29 August 2017

language of work or name

English

0 references

publication date

22 May 2013

1 reference

Expert Opinion on Biological Therapy

29 August 2017

published in

1 reference

29 August 2017

volume

13 Suppl 1

1 reference

29 August 2017

page(s)

S1-22

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.799132

29 August 2017

1 reference

Review of 1027 patients with newly diagnosed multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.799132

Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.799132

A monoclonal gammopathy precedes multiple myeloma in most patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.799132

Epidemiology of multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.799132

21 January 2018

Cancer statistics, 2010

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.799132

Patterns of survival in multiple myeloma: a population-based study of patients diagnosed in Sweden from 1973 to 2003.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.799132

Recent major improvement in long-term survival of younger patients with multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.799132

Improved survival in multiple myeloma and the impact of novel therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.799132

Shifts in the therapeutic paradigm for patients newly diagnosed with multiple myeloma: maintenance therapy and overall survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.799132

Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised p

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.799132

Improvement in survival of older adults with multiple myeloma: results of an updated period analysis of SEER data

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.799132

Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.799132

Myeloma management guidelines: a consensus report from the Scientific Advisors of the International Myeloma Foundation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.799132

Advances in imaging and the management of myeloma bone disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.799132

Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.799132

International staging system for multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.799132

Prognostic value of the serum free light chain ratio in newly diagnosed myeloma: proposed incorporation into the international staging system

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.799132

Incorporation of the bone marker carboxy-terminal telopeptide of type-1 collagen improves prognostic information of the International Staging System in newly diagnosed symptomatic multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.799132

The role of anatomic and functional staging in myeloma: description of Durie/Salmon plus staging system

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.799132

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.799132

Pathogenesis of myeloma bone disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.799132

Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.799132

Initial genome sequencing and analysis of multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.799132

High expression levels of the mammalian target of rapamycin inhibitor DEPTOR are predictive of response to thalidomide in myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.799132

Linking DNA methylation and histone modification: patterns and paradigms

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.799132

The MMSET histone methyl transferase switches global histone methylation and alters gene expression in t(4;14) multiple myeloma cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.799132

Prognostic significance of copy-number alterations in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.799132

miR-29b sensitizes multiple myeloma cells to bortezomib-induced apoptosis through the activation of a feedback loop with the transcription factor Sp1

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.799132

DNA-demethylating and anti-tumor activity of synthetic miR-29b mimics in multiple myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.799132

Promises and challenges of MicroRNA-based treatment of multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.799132

MicroRNAs in the pathobiology of multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.799132

Insights into the multistep transformation of MGUS to myeloma using microarray expression analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.799132

Global gene expression profiling of multiple myeloma, monoclonal gammopathy of undetermined significance, and normal bone marrow plasma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.799132

Gene expression profiling of multiple myeloma reveals molecular portraits in relation to the pathogenesis of the disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.799132

The molecular classification of multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.799132

A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.799132

MicroRNAs regulate critical genes associated with multiple myeloma pathogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.799132

Immunoglobulin gene rearrangements and the pathogenesis of multiple myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.799132

Cyclin D dysregulation: an early and unifying pathogenic event in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.799132

Clinical implications of t(11;14)(q13;q32), t(4;14)(p16.3;q32), and -17p13 in myeloma patients treated with high-dose therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.799132

Impact of risk stratification on outcome among patients with multiple myeloma receiving initial therapy with lenalidomide and dexamethasone

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.799132

International Myeloma Working Group molecular classification of multiple myeloma: spotlight review.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.799132

Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.799132

Smoldering (asymptomatic) multiple myeloma: current diagnostic criteria, new predictors of outcome, and follow-up recommendations

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.799132

Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.799132

How I treat multiple myeloma in younger patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.799132

High-dose therapy and autologous blood stem-cell transplantation compared with conventional treatment in myeloma patients aged 55 to 65 years: long-term results of a randomized control trial from the Group Myelome-Autogreffe

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.799132

Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: final results of phase III US Intergroup Trial S9321.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.799132

Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.799132

International Myeloma Working Group guidelines for the management of multiple myeloma patients ineligible for standard high-dose chemotherapy with autologous stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.799132

Nonmyeloablative allografting for newly diagnosed multiple myeloma: the experience of the Gruppo Italiano Trapianti di Midollo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.799132

Therapeutic approaches for newly diagnosed multiple myeloma patients in the era of novel drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.799132

Multicenter, randomized, double-blind, placebo-controlled study of thalidomide plus dexamethasone compared with dexamethasone as initial therapy for newly diagnosed multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.799132

Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.799132

Bortezomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma: results of the IFM 2005-01 phase III trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.799132

Cyclophosphamide, bortezomib and dexamethasone induction for newly diagnosed multiple myeloma: high response rates in a phase II clinical trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.799132

Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.799132

A randomized phase 3 study on the effect of thalidomide combined with adriamycin, dexamethasone, and high-dose melphalan, followed by thalidomide maintenance in patients with multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.799132

Cyclophosphamide, thalidomide, and dexamethasone (CTD) as initial therapy for patients with multiple myeloma unsuitable for autologous transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.799132

Bortezomib, dexamethasone, cyclophosphamide and lenalidomide combination for newly diagnosed multiple myeloma: phase 1 results from the multicenter EVOLUTION study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.799132

Randomized, multicenter, phase 2 study (EVOLUTION) of combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in previously untreated multiple myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.799132

Total Therapy 3 for multiple myeloma: prognostic implications of cumulative dosing and premature discontinuation of VTD maintenance components, bortezomib, thalidomide, and dexamethasone, relevant to all phases of therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.799132

Superior results of Total Therapy 3 (2003-33) in gene expression profiling-defined low-risk multiple myeloma confirmed in subsequent trial 2006-66 with VRD maintenance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.799132

Early versus delayed autologous transplantation after immunomodulatory agents-based induction therapy in patients with newly diagnosed multiple myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.799132

Single versus double autologous stem-cell transplantation for multiple myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.799132

Long-term follow-up of autotransplantation trials for multiple myeloma: update of protocols conducted by the intergroupe francophone du myelome, southwest oncology group, and university of arkansas for medical sciences

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.799132

Oral melphalan, prednisone, and thalidomide in elderly patients with multiple myeloma: updated results of a randomized controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.799132

Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.799132

Phase III study of the value of thalidomide added to melphalan plus prednisone in elderly patients with newly diagnosed multiple myeloma: the HOVON 49 Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.799132

Efficacy of melphalan and prednisone plus thalidomide in patients older than 75 years with newly diagnosed multiple myeloma: IFM 01/01 trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.799132

Melphalan and prednisone plus thalidomide or placebo in elderly patients with multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.799132

Thalidomide for previously untreated elderly patients with multiple myeloma: meta-analysis of 1685 individual patient data from 6 randomized clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.799132

Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.799132

Bortezomib plus melphalan and prednisone compared with melphalan and prednisone in previously untreated multiple myeloma: updated follow-up and impact of subsequent therapy in the phase III VISTA trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.799132

Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.799132

Bortezomib as induction before autologous transplantation, followed by lenalidomide as consolidation-maintenance in untreated multiple myeloma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.799132

Major tumor shrinking and persistent molecular remissions after consolidation with bortezomib, thalidomide, and dexamethasone in patients with autografted myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.799132

Consolidation therapy with low-dose thalidomide and prednisolone prolongs the survival of multiple myeloma patients undergoing a single autologous stem-cell transplantation procedure

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.799132

Thalidomide and hematopoietic-cell transplantation for multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.799132

Thalidomide-dexamethasone versus interferon-alpha-dexamethasone as maintenance treatment after ThaDD induction for multiple myeloma: a prospective, multicentre, randomised study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.799132

Lenalidomide after stem-cell transplantation for multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.799132

Efficacy and safety of once-weekly bortezomib in multiple myeloma patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.799132

Bortezomib-induced peripheral neuropathy in multiple myeloma: a comparison between previously treated and untreated patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.799132

Single-agent bortezomib in previously untreated multiple myeloma: efficacy, characterization of peripheral neuropathy, and molecular correlations with response and neuropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.799132

Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.799132

Rates of venous thromboembolism in multiple myeloma patients undergoing immunomodulatory therapy with thalidomide or lenalidomide: a systematic review and meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.799132

Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.799132

Expanded safety experience with lenalidomide plus dexamethasone in relapsed or refractory multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.799132

Current multiple myeloma treatment strategies with novel agents: a European perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.799132

Impact of high-risk cytogenetics and prior therapy on outcomes in patients with advanced relapsed or refractory multiple myeloma treated with lenalidomide plus dexaméthasone

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.799132

Bortezomib plus dexamethasone induction improves outcome of patients with t(4;14) myeloma but not outcome of patients with del(17p).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.799132

Treatment of multiple myeloma: a comprehensive review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.799132

Individualizing treatment of patients with myeloma in the era of novel agents.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.799132

Diagnostic evaluation of t(4;14) in multiple myeloma and evidence for clonal evolution.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.799132

Pharmacogenomics of bortezomib test-dosing identifies hyperexpression of proteasome genes, especially PSMD4, as novel high-risk feature in myeloma treated with Total Therapy 3

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.799132

Polymorphisms in the multiple drug resistance protein 1 and in P-glycoprotein 1 are associated with time to event outcomes in patients with advanced multiple myeloma treated with bortezomib and pegylated liposomal doxorubicin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.799132

Genomic screening for genes silenced by DNA methylation revealed an association between RASD1 inactivation and dexamethasone resistance in multiple myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.799132

Overexpression of the PSMB5 gene contributes to bortezomib resistance in T-lymphoblastic lymphoma/leukemia cells derived from Jurkat line

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.799132

Different mutants of PSMB5 confer varying bortezomib resistance in T lymphoblastic lymphoma/leukemia cells derived from the Jurkat cell line

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.799132

Point mutation of the proteasome beta5 subunit gene is an important mechanism of bortezomib resistance in bortezomib-selected variants of Jurkat T cell lymphoblastic lymphoma/leukemia line

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.799132

Molecular basis of bortezomib resistance: proteasome subunit beta5 (PSMB5) gene mutation and overexpression of PSMB5 protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.799132

Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.799132

Carfilzomib can induce tumor cell death through selective inhibition of the chymotrypsin-like activity of the proteasome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.799132

A novel orally active proteasome inhibitor ONX 0912 triggers in vitro and in vivo cytotoxicity in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.799132

Combination of novel proteasome inhibitor NPI-0052 and lenalidomide trigger in vitro and in vivo synergistic cytotoxicity in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.799132

A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.799132

Histone deacetylase inhibitors for cancer therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.799132

Small-molecule inhibition of proteasome and aggresome function induces synergistic antitumor activity in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.799132

Aggresome induction by proteasome inhibitor bortezomib and alpha-tubulin hyperacetylation by tubulin deacetylase (TDAC) inhibitor LBH589 are synergistic in myeloma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.799132

Transcriptional signature of histone deacetylase inhibition in multiple myeloma: biological and clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.799132

Mechanism of action of proteasome inhibitors and deacetylase inhibitors and the biological basis of synergy in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.799132

Phase I study of vorinostat in combination with bortezomib for relapsed and refractory multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.799132

Alternate day pomalidomide retains anti-myeloma effect with reduced adverse events and evidence of in vivo immunomodulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.799132

Phase I study of an immunomodulatory thalidomide analog, CC-4047, in relapsed or refractory multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.799132

The anti-cancer agents lenalidomide and pomalidomide inhibit the proliferation and function of T regulatory cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.799132

Lenalidomide and CC-4047 inhibit the proliferation of malignant B cells while expanding normal CD34+ progenitor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.799132

The thalidomide analogue, CC-4047, induces apoptosis signaling and growth arrest in childhood acute lymphoblastic leukemia cells in vitro and in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.799132

Dexamethasone synergizes with lenalidomide to inhibit multiple myeloma tumor growth, but reduces lenalidomide-induced immunomodulation of T and NK cell function

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.799132

Pomalidomide (CC4047) plus low-dose dexamethasone as therapy for relapsed multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.799132

Pomalidomide plus low-dose dexamethasone in myeloma refractory to both bortezomib and lenalidomide: comparison of 2 dosing strategies in dual-refractory disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.799132

Phase II trial of temsirolimus in patients with relapsed or refractory multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.799132

Combination of the mTOR inhibitor rapamycin and CC-5013 has synergistic activity in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.799132

Weekly bortezomib in combination with temsirolimus in relapsed or relapsed and refractory multiple myeloma: a multicentre, phase 1/2, open-label, dose-escalation study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.799132

Antimyeloma activity of heat shock protein-90 inhibition.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.799132

IPI-504, a novel and soluble HSP-90 inhibitor, blocks the unfolded protein response in multiple myeloma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.799132

Tanespimycin with bortezomib: activity in relapsed/refractory patients with multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.799132

Perifosine, an oral bioactive novel alkylphospholipid, inhibits Akt and induces in vitro and in vivo cytotoxicity in human multiple myeloma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.799132

Perifosine synergistically enhances TRAIL-induced myeloma cell apoptosis via up-regulation of death receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.799132

Perifosine plus bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma previously treated with bortezomib: results of a multicenter phase I/II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.799132

Anti-CS1 humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces antibody-dependent cellular cytotoxicity in the bone marrow milieu

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.799132

Combinatorial efficacy of anti-CS1 monoclonal antibody elotuzumab (HuLuc63) and bortezomib against multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.799132

Elotuzumab in combination with lenalidomide and low-dose dexamethasone in relapsed or refractory multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.799132

Targeted inhibition of interleukin-6 with CNTO 328 sensitizes pre-clinical models of multiple myeloma to dexamethasone-mediated cell death

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.799132

Treatment of bendamustine and prednisone in patients with newly diagnosed multiple myeloma results in superior complete response rate, prolonged time to treatment failure and improved quality of life compared to treatment with melphalan and predniso

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.799132

Combined bendamustine, prednisolone and thalidomide for refractory or relapsed multiple myeloma after autologous stem-cell transplantation or conventional chemotherapy: results of a Phase I clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.799132

Combination of bendamustine, lenalidomide, and dexamethasone (BLD) in patients with relapsed or refractory multiple myeloma is feasible and highly effective: results of phase 1/2 open-label, dose escalation study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.799132

Phase I/II trial assessing bendamustine plus bortezomib combination therapy for the treatment of patients with relapsed or refractory multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.799132

Prospective, randomized study of single compared with double autologous stem-cell transplantation for multiple myeloma: Bologna 96 clinical study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.799132

Prediction of Survival in Multiple Myeloma Based on Gene Expression Profiles Reveals Cell Cycle and Chromosomal Instability Signatures in High-Risk Patients and Hyperdiploid Signatures in Low-Risk Patients: A Study of the Intergroupe Francophone du M

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.799132

Clinical Course and Prognosis of Smoldering (Asymptomatic) Multiple Myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.799132

Continuous Lenalidomide Treatment for Newly Diagnosed Multiple Myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.799132

Analysis of genetic abnormalities provides insights into genetic evolution of hyperdiploid myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.799132

Lenalidomide Maintenance after Stem-Cell Transplantation for Multiple Myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.799132

10.1517/14712598.2013.799132

21 January 2018

Identifiers

DOI

1 reference

29 August 2017

1 reference